HER2 overexpression suggests a rationale for investigating HER2-directed therapies such as trastuzumab, pertuzumab, and lapatinib in clinical trials, which have demonstrated efficacy in HER2-positive breast and gastric cancers [57,58]. Here, ERBB2 is linked to gastric cancer.